Short Bowel Syndrome
- 1 January 1990
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 45 (1) , 77-83
- https://doi.org/10.1159/000200267
Abstract
Nine patients with short bowel syndrome and high intestinal output received octreotide either intravenously (50-100 .mu.g t.i.d.) or subcutaneously (100 .mu.g b/i.d.) on 2 test days. In the 6 patients with net secretory output, there was a reduction in mean daily intestinal output of 0.5-5.0 kg; total daily intestinal output of sodium and potassium was also reduced significantly. Of the 3 patients with a net absorptive state, there was a worsening of output in 2 and no improvement occurred in the other. Two patients with net secretory output received long-term octreotide therapy, allowing a reduction in daily intravenous fluid intake of 1.0-1.5 litres.Keywords
This publication has 6 references indexed in Scilit:
- Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestineAlimentary Pharmacology & Therapeutics, 1989
- The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short‐bowel syndromeAlimentary Pharmacology & Therapeutics, 1989
- Effect of Somatostatin on Salivary Secretion in ManDigestion, 1986
- HOME PARENTERAL NUTRITION IN THE UNITED KINGDOM AND IRELANDThe Lancet, 1986
- Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue.Gut, 1986
- Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea.BMJ, 1984